Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants
A.-K. Reuschl, L. G. Thorne, M. X. V. Whelan, R. Ragazzini, W. Furnon, V. M. Cowton, G. de Lorenzo, D. Mesner, J. E. Turner, G. Dowgier, N. Bogoda, P. Bonfanti, M. Palmarini, A. H. Patel, C. Jolly, G. J. Towers
Abstract
SARS-CoV-2 adaptation to humans is evidenced by the emergence of variants of concern (VOCs) with distinct genotypes and phenotypes that facilitate immune escape and enhance transmission frequency. Most recently Omicron subvariants have emerged with heavily mutated spike proteins which facilitate re-infection of immune populations through extensive antibody escape driving replacement of previously-dominant VOCs Alpha and Delta. Interestingly, Omicron is the first VOC to produce distinct subvariants. Here, we demonstrate that later Omicron subvariants, particularly BA.4 and BA.5, have evolved an enhanced capacity to suppress human innate immunity when compared to earliest subvariants BA.1 and BA.2. We find that, like previously dominant VOCs, later Omicron subvariants tend to increase expression of viral innate immune antagonists Orf6 and nucleocapsid. We show Orf6 to be a key contributor to enhanced innate immune suppression during epithelial replication by BA.5 and Alpha, reducing innate immune signaling through IRF3 and STAT1. Convergent VOC evolution of enhanced innate immune antagonist expression suggests common pathways of adaptation to humans and links VOC, and in particular Omicron subvariant, dominance to improved innate immune evasion.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 Omicron subvariants evolved to promote further escape from MHC-I recognition
M. Moriyama, C. Lucas, … A. Iwasaki·bioRxiv·May 4, 2022
- Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant
L. G. Thorne, M. Bouhaddou, … N. J. Krogan·bioRxiv·Jun 6, 2021
- Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response
L. Shalamova, U. Felgenhauer, … F. Weber·bioRxiv·Jan 20, 2022
- Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75
- SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses
D. Tandel, V. Sah, … K. H. Harshan·bioRxiv·Feb 22, 2022
- Global landscape of the host response to SARS-CoV-2 variants reveals viral evolutionary trajectories
Mehdi Bouhaddou, Ann‐Kathrin Reuschl, … Nevan J. Krogan·bioRxiv·Oct 19, 2022